Eftozanermin alfa联合venetoclax在急性髓系白血病临床前模型及患者中的活性
研究评估TRAIL受体激动融合蛋白eftozanermin alfa(eftoza)联合B细胞淋巴瘤蛋白-2选择性抑制剂venetoclax在急性髓系白血病(AML)中的活性。临床前模型中两药同时激活外源性和内源性凋亡信号通路增强活性,且依赖死亡受体4/5表达而不依赖TP53或FLT3-ITD状态。1期试验显示复发/难治AML中联合治疗总体缓解率30%(7/23),单药无肿瘤缓解。
要点
- Eftoza联合venetoclax在AML细胞系及患者来源模型增强凋亡活性,依赖DR4/DR5表达。
- 1期试验中联合治疗总体缓解率30%(7/23),DR4/DR5阳性患者为67%(4/6)。
- 单药治疗4例中2例(50%)报告治疗相关不良事件,联合治疗23例中18例(78%)。
核心结论
- Eftoza联合venetoclax同时激活外源性和内源性凋亡信号通路,在复发/难治AML中可能较venetoclax单药改善临床获益且毒性可接受。
研究设计与样本
- 临床前AML细胞系及患者来源的离体/体内模型研究,联合1期临床试验评估eftoza单药及联合venetoclax的安全性/耐受性。
- 1期试验纳入复发/难治AML患者,单药组4例,联合组23例。
- 试验注册号NCT03082209。
主要发现
- Eftoza单药或联合venetoclax的活性需要质膜死亡受体4/5(DR4/DR5)表达,但不依赖TP53或FLT3-ITD状态。
- 联合治疗组总体缓解率30%(7/23),包括4例完全缓解、2例伴血液学恢复不完全的完全缓解和1例形态学无白血病状态。
- DR4/DR5表达阳性的原始细胞患者联合治疗缓解率67%(4/6)。
- Eftoza单药治疗未观察到肿瘤缓解。
- 单药组治疗相关不良事件2/4(50%),联合组18/23(78%)。
关键数值与推荐
- 联合治疗总体缓解率30%(7/23;4例CR,2例CRi,1例MLFS)。
- DR4/DR5阳性患者联合治疗缓解率67%(4/6)。
- 治疗相关不良事件:单药组2/4(50%),联合组18/23(78%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activation of apoptosis in malignant cells is an established strategy for controlling cancer and is potentially curative. To assess the impact of concurrently inducing the extrinsic and intrinsic apoptosis-signaling pathways in acute myeloid leukemia (AML), we evaluated activity of the TRAIL receptor agonistic fusion protein eftozanermin alfa (eftoza; ABBV-621) in combination with the B-cell lymphoma protein-2 selective inhibitor venetoclax in preclinical models and human patients. Simultaneously stimulating intrinsic and extrinsic apoptosis-signaling pathways with venetoclax and eftoza, respectively, enhanced their activities in AML cell lines and patient-derived ex vivo/in vivo models. Eftoza activity alone or plus venetoclax required death receptor 4/5 (DR4/DR5) expression on the plasma membrane but was independent of TP53 or FLT3-ITD status. The safety/tolerability of eftoza as monotherapy and in combination with venetoclax was demonstrated in patients with relapsed/refractory AML in a phase 1 clinical trial. Treatment-related adverse events were reported in 2 of 4 (50%) patients treated with eftoza monotherapy and 18 of 23 (78%) treated with eftoza plus venetoclax. An overall response rate of 30% (7/23; 4 complete responses [CRs], 2 CRs with incomplete hematologic recovery, and 1 morphologic leukemia-free state) was reported in patients who received treatment with eftoza plus venetoclax and 67% (4/6) in patients with myoblasts positive for DR4/DR5 expression; no tumor responses were observed with eftoza monotherapy. These data indicate that combination therapy with eftoza plus venetoclax to simultaneously activate the extrinsic and intrinsic apoptosis-signaling pathways may improve clinical benefit compared with venetoclax monotherapy in relapsed/refractory AML with an acceptable toxicity profile. This trial was registered at www.clinicaltrials.gov as #NCT03082209.
引用
- Tahir SK, Calvo E, Carneiro BA, et al. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023. PMID: 36720090. doi:10.1182/blood.2022017333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。